Table 2 : Previous antidiabetic treatment (N=250).


Treatment Values

Oral antidiabetic drugs*, n (%) 241 (96.4)
Metformin 197 (78.8)
Sulphonylureas 143 (57.2)
DPP4 Inhibitors 32 (12.8)
Rapid-acting insulin secretagogues 22 (8.8)
Thiazolidenediones 15 (6)
Alpha-glucosidase inhibitors 15 (6)
GLP1 analogs 2 (0.8)
NPH insulin, n (%) 38 (15.2)
No. NPH insulin injections/day (mean ± S.D.) 1.8 ± 0.4
Total daily dose of NPH insulin, UI (mean ± S.D.) 38.1 ± 15.8
Time from treatment initiation with insulin, months (mean ± S.D.) 48.5 ± 47.2

*Multiple-choice question. DPP4, dipeptidyl peptidase 4; S.D., standard deviation; GLP1, Glucagon-like peptide-1.

Bellido-Guerrero et al.Journal of Diabetes Research and Clinical Metabolism  2013 2:20DOI : 10.7243/2050-0866-2-20